Edition:
India

Erytech Pharma SA (ERYP.PA)

ERYP.PA on Paris Stock Exchange

16.20EUR
15 Dec 2017
Change (% chg)

€0.20 (+1.25%)
Prev Close
€16.00
Open
€16.18
Day's High
€16.20
Day's Low
€15.89
Volume
50,620
Avg. Vol
83,167
52-wk High
€30.20
52-wk Low
€12.10

Chart for

About

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The... (more)

Overall

Beta: 0.86
Market Cap(Mil.): €284.01
Shares Outstanding(Mil.): 11.74
Dividend: --
Yield (%): --

Financials

BRIEF-Erytech Pharma ‍announces pricing of global offering of 5.4 mln new ordinary shares​

* ‍ANNOUNCES PRICING OF GLOBAL OFFERING TO SPECIFIED CATEGORIES OF INVESTORS OF AGGREGATE OF 5.4 MILLION NEW ORDINARY SHARES​

10 Nov 2017

BRIEF-Erytech Pharma announces trading suspension of its ordinary shares on Euronext paris​

* ERYTECH ANNOUNCES TRADING SUSPENSION OF ITS ORDINARY SHARES ON EURONEXT PARIS

10 Nov 2017

BRIEF-Erytech Pharma 9M net loss widens to 20.8 million euros

* ANNOUNCED ON MONDAY 9M NET LOSS OF EUR 20.8 MLN VS PROFIT OF EUR 16.1 MLN YEAR AGO

07 Nov 2017

BRIEF-Erytech Pharma sees U.S. IPO of up to 4.26 mln ordinary shares in form of ADSs

* Erytech Pharma SA sees U.S. IPO of up to 4.26 million ordinary shares in form of American Depositary Shares, or ADSs‍​ - sec filing

07 Nov 2017

BRIEF-Erytech Pharma ‍announces resubmission of european marketing authorization application for GRASPA

* ‍ANNOUNCES RESUBMISSION OF EUROPEAN MARKETING AUTHORIZATION APPLICATION FOR GRASPA IN ACUTE LYMPHOBLASTIC LEUKEMIA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

10 Oct 2017

BRIEF-Erytech Pharma files for U.S. IPO of up to $100 mln of ADSS

* Erytech Pharma Sa files for U.S. IPO of up to $100 million of ADSS - SEC filing‍​

07 Oct 2017

BRIEF-Erytech Pharma H1 net loss widens to ‍​14.0 million euros

* ERYTECH REPORTS FIRST HALF 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

11 Sep 2017

BRIEF-Erytech Pharma's complete results demonstrate statistically improvement in overall survival and progression-free survival ‍​

* COMPLETE DATA DEMONSTRATE A STATISTICALLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL ‍​

08 Sep 2017

BRIEF-Erytech announces collaboration with Queen’s University

* ERYTECH ANNOUNCES COLLABORATION WITH QUEEN’S UNIVERSITY TO ADVANCE ITS PRODUCT CANDIDATE FOR RARE METABOLIC DISORDERS

12 Jul 2017

Earnings vs. Estimates